Entrada Quarterly Newsletter for the Duchenne Community

Entrada remains hard at work advancing our Duchenne programs and we continue to gain momentum. As part of our commitment to providing clear, timely and transparent updates on our progress, we're pleased to share the latest issue of our quarterly community newsletter.

To receive future updates and newsletters directly in your inbox, click here.

News Spotlight

Today we announced:

- Positive initial data from the first cohort of our Phase 1/2 ELEVATE-44-201 study for ambulatory children and young adults living with Duchenne who are exon 44 skipping amenable
- Enrollment for our ELEVATE-44-201 and ELEVATE-45-201 studies is ongoing
- Updated timing for our ELEVATE-50-201 and ELEVATE-51-201 regulatory submissions



Click to read the full May 7, 2026, news release on our first cohort data

Click to read our May 7, 2026, first quarter financial results news release

Updates on Clinical Studies

Enabled by our Endosomal Escape Vehicle (EEV™) Platform, we are working to quickly advance our lead programs for people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. Read on for our progress.

Exon 44 Skipping Amenable Community

ELEVATE-44-201 Study: Continuing to Enroll Participants

The ELEVATE-44-201 study is a global, randomized, double-blind, placebo-controlled* Phase 1/2 study evaluating the safety, tolerability and effectiveness of ENTR-601-44 in ambulatory children and young adults living with Duchenne who are amenable to exon 44 skipping. The study is taking place in the U.K., Belgium, Italy and Spain.

This week, we reached an early but important milestone: we shared initial data from the first cohort in this study. While these initial findings are from a small group (8 participants) and at the lowest dose (6 mg/kg), they mark a meaningful step forward.

Highlights from the results include:

- Favorable safety and tolerability, which is the objective for this study. There were no discontinuations and no serious adverse events. Markers of kidney function were normal.
- Earlier-than-expected functional responses: treated participants achieved a statistically significant improvement in time to rise (TTR) velocity.
- Dystrophin increase of 2.36% over 4.00% baseline in treated participants. While this is lower than we had originally expected, our previous estimates were based on data from adults — both nonhuman primates and those who participated in our healthy normal volunteer study. We've recently received data from a juvenile nonhuman primate study which mirrors the results we've seen from the first cohort and suggests we may see a higher level of dystrophin expression as well as continued functional improvement in the second cohort.

All participants in the first cohort are now in the open-label portion of the study, where they receive six additional doses of 6 mg/kg of ENTR-601-44. The second cohort (12 mg/kg) is now enrolling participants.

We are on track to report data from the first cohort's open-label extension period, as well as the second cohort by the end of 2026, with the third cohort to follow.

To learn more about the study, visit www.elevate44study.com

ELEVATE-44-102 Study: Planning to Re-Engage with FDA to Explore Increasing Dose Levels

In February 2025, the U.S. FDA authorized initiation of the ELEVATE-44-102 study for non-ambulatory and ambulatory adults living with Duchenne who are amenable to exon 44 skipping. We believe this clinical study, in the underserved adult Duchenne population with advanced disease, would be best initiated at the highest advisable starting dose. We plan to re-engage with the FDA to discuss and will provide an update on the study design and timing following these interactions.

Exon 45 Skipping Amenable Community

ELEVATE-45-201 Study: Continuing to Enroll Participants

The ELEVATE-45-201 study is a global, randomized, double-blind placebo-controlled* Phase 1/2 study evaluating the safety, tolerability and effectiveness of ENTR-601-45 in ambulatory children and young adults living with Duchenne who are amenable to exon 45 skipping. The study is taking place in the U.K., the Netherlands, Belgium, Italy and Spain.

The first cohort has initiated dosing and we are on track to report data from the first cohort in mid-2026 with data from the second and third cohorts to follow.

To learn more about the study, visit www.elevate45study.com

Exon 50 Skipping Amenable Community

ELEVATE-50-201 Study: Received Regulatory Authorization to Initiate in the U.K.

The ELEVATE-50-201 study is a global, randomized, double-blind placebo-controlled* Phase 1/2 study evaluating the safety, tolerability and effectiveness of ENTR-601-50 in ambulatory children and young adults living with Duchenne who are amenable to exon 50 skipping.

We have received regulatory authorization from the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics committee to initiate the study in the U.K. We now expect to submit additional regulatory applications and obtain authorization in the EU following a review of data from the ongoing clinical studies. We will continue to provide updates on the timing of this study as soon as they become available.

Exon 51 Skipping Amenable Community

We now expect to submit regulatory filings for a Phase 1/2 study of ENTR-601-51 and obtain authorization following a review of data from the ongoing clinical studies. We will continue to provide updates on the timing of this study as soon as they become available.

**A placebo looks like a study drug but does not have any medicine in it. Researchers use placebos to help make sure any changes in participants' health are actually caused by the study drug.*

Clinical Study Participants Make Progress Possible

We are incredibly grateful to those living with Duchenne, their care partners and the study investigators and personnel who are taking part in our clinical study. Advancing potential therapies is not possible without the participation of the community, and we are inspired every day by their commitment to make progress for those living with Duchenne.

Are You a Nonprofit Organization? Apply for 2026 DREAMS Grant Program!

Our DREAMS Grant Program is back for its fourth year! Two nonprofit organizations will each receive a $50,000 USD grant to fund efforts within the Duchenne muscular dystrophy community that better identify, understand and reach those who are currently underrepresented or underserved. In 2026, DREAMS Grants will be awarded to one U.S.-based nonprofit and one nonprofit in the U.K. or EU, with recipients being reviewed and selected by an Independent Grant Review Committee composed of Duchenne community members.

The deadline to apply is July 9, 2026.
To learn more and apply, visit: www.entradabx.com/dreams

Recent Community Events

Launched our internal Ambassador Program to equip Entrada employees with the tools and guidance to participate at community events.



Learned from international advocates and experts at World Duchenne Organization's Global Duchenne Community Meeting in Rome, Italy.

Sponsored the 23rd International Conference on Duchenne and Becker Muscular Dystrophy hosted by Parent Project aps in Rome, Italy.



Came together for a card-writing initiative in celebration of Rare Disease Day, where colleagues wrote messages for care partners and siblings.

Presented our research and connected with the community at the Muscular Dystrophy Association's Clinical & Scientific Conference in Orlando, FL.

Shared an update on our recent research at the World Duchenne Organization's Virtual Post-MDA webinar.

Upcoming Community Events

We support, participate in and hold events to connect with the community and work toward solutions together. Here's what we're up to for the next few months:

May 21-24:
CureDuchenne 2026 FUTURES (Orlando, FL)

May 22-24:
Parent Project Spain International Conference (Madrid, Spain)

May 26-27:
World Duchenne Organization's Duchenne Care Conference 2026 (Virtual)

June 4:
Entrada Meeting with WDO's Duchenne Community Advisory Board (CAB) (Zaandam, the Netherlands)

June 11:
Jett Foundation Silver Soiree (Quincy, MA)

June 25-27:
PPMD's 2026 Annual Conference (Orlando, FL)

July 7-11:
ICMMO 2026 (Florence, Italy)

July 9:
Entrada DREAMS Grant Program (Applications close at 11:59 pm EDT)

We'd love to connect!

Contact Sarah Friedhoff, our Head of Patient Advocacy, at PatientAdvocacy@entradabx.com.

To help make this newsletter accessible to more readers, we offer automated translations of our original English content. Because these translations are produced by software, they may contain grammatical mistakes, differences in interpretation or unintended mistranslations.

This document includes forward-looking statements that involve risks and uncertainties. These statements are not guarantees of future results and should not be used for investment decisions

Follow us on social for news, updates and more.